U.S. Application No. 10/589,892 Attorney Docket No.: 03327.2355

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

- 1-8. (Cancelled).
- 9. (Currently amended). A method for prophylaxis treatment or inhibition of migraine which comprises

administering a therapeutically effective amount of a selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors to a patient, wherein the selective dual antagonist is a single compound; and

treating or inhibiting migraine in a migraine patient or a patient who has been diagnosed to be migraine or in whom periodical attacks of migraine occur.

- 10. (Cancelled).
- 11. (Withdrawn). The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors comprises:
 - a) a 5-HT_{2B} receptor antagonistic compound as a first ingredient having a selective binding affinity to the 5-HT_{2B} receptor, and
 - b) a 5-HT₇ receptor antagonistic compound as a second ingredient having a selective binding affinity to the 5-HT₇ receptor.
- 12. (Previously presented). The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors comprises a dual antagonistic compound

U.S. Application No. 10/589,892 Attorney Docket No.: 03327.2355

for the 5-HT $_{2B}$ and 5-HT $_7$ receptors having a selective binding affinity to both of the 5-HT $_{2B}$ and 5-HT $_7$ receptors.

- 13. (Previously presented). The method of claim 9, wherein the Ki or IC_{50} values for the 5-HT_{2B} and 5-HT₇ receptors are respectively one-hundredth or less of those of each of α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.
- 14. (Previously presented). The method of claim 9, wherein the binding affinities for the 5-HT2_B and 5-HT₇ receptors are higher than those of each of α_1 , M_1 , D_2 , 5-HT_{1A}, 5-HT₃, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.
- 15. (Previously presented). The method of claim 9, wherein the binding affinities for the 5-HT2_B and 5-HT₇ receptors are higher than those of each of α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{2A}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.
- 16. (Previously presented). The method of claim 9, wherein the Ki or IC_{50} values for the 5-HT2_B and 5-HT₇ receptors are respectively one-tenth or less of those of each of α_1 , M_1 , D_2 , 5-HT_{1A}, 5-HT_{1B}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.
- 17. (Previously presented). The method of claim 9, wherein the Ki or IC_{50} values for the 5-HT2_B and 5-HT₇ receptors are respectively one-tenth or less of those of each of α_1 , M_1 , D_2 , 5-HT_{1A}, 5-HT_{2A}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.

U.S. Application No. 10/589,892 Attorney Docket No.: 03327.2355

18. (Previously presented). The method of claim 9, wherein the Ki or IC_{50} values for the 5-HT_{2B} and 5-HT₇ receptors are respectively one-hundredth or less of those of each of α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.

19. (New). The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT_{7} receptors is N-(diaminomethylene)-9-hydroxy-9H-fluorene-2-carboxamide.